Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control

Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control

Abstract Aims/Introduction Painful diabetic peripheral neuropathy (pDPN) is associated with small nerve fiber degeneration and regeneration. This study investigated whether the presence of pDPN might influence nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control....

Full description

Bibliographic Details
Main Authors:	Georgios Ponirakis, Muhammad A Abdul‐Ghani, Amin Jayyousi, Mahmoud A Zirie, Murtaza Qazi, Hamad Almuhannadi, Ioannis N Petropoulos, Adnan Khan, Hoda Gad, Osama Migahid, Ayman Megahed, Salma Al‐Mohannadi, Fatema AlMarri, Fatima Al‐Khayat, Ziyad Mahfoud, Hanadi Al Hamad, Marwan Ramadan, Ralph DeFronzo, Rayaz A Malik
Format:	Article
Language:	English
Published:	Wiley 2021-09-01
Series:	Journal of Diabetes Investigation
Subjects:	Corneal confocal microscopy Exenatide Painful diabetic neuropathy
Online Access:	https://doi.org/10.1111/jdi.13544

Similar Items

Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control
by: Georgios Ponirakis, et al.
Published: (2021-11-01)

Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study
by: Hanadi Al Hamad, et al.
Published: (2020-04-01)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
by: Saunders WB, et al.
Published: (2016-07-01)

Association of Cerebral Ischemia With Corneal Nerve Loss and Brain Atrophy in MCI and Dementia
by: Georgios Ponirakis, et al.
Published: (2021-06-01)

Glycated hemoglobin versus oral glucose tolerance test in the identification of subjects with prediabetes in Qatari population
by: Saadallah Iskandar, et al.
Published: (2019-08-01)

Prevalence and risk factors for diabetic peripheral neuropathy, neuropathic pain and foot ulceration in the Arabian Gulf region
by: Georgios Ponirakis, et al.
Published: (2022-09-01)

The Changes of Lipidomic Profiles Reveal Therapeutic Effects of Exenatide in Patients With Type 2 Diabetes
by: Lin Zhang, et al.
Published: (2022-03-01)

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
by: Courtney H, et al.
Published: (2017-03-01)

Effects of Short-Term Exenatide Treatment on Regional Fat Distribution, Glycated Hemoglobin Levels, and Aortic Pulse Wave Velocity of Obese Type 2 Diabetes Mellitus Patients
by: Ju-Young Hong, et al.
Published: (2016-03-01)

Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes
by: Georgios Ponirakis, et al.
Published: (2022-10-01)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
by: Angelos Kyriacou, et al.
Published: (2010-08-01)

EFFECT OF PHARMACOLOGICAL PRECONDITIONING WITH INCRETINOMIMETICS EXENATIDE AND VILDAGLIPTIN ON THE SURVIVAL OF ISCHEMIC TISSUES
by: Alla Tarasova, et al.
Published: (2017-12-01)

Addendum 2: Forum for Injection Technique, India
by: Sanjay Kalra, et al.
Published: (2014-01-01)

GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
by: Joshua J. Neumiller, et al.
Published: (2022-07-01)

Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications
by: Edwards KL, et al.
Published: (2006-09-01)

New indications for exenatide therapy of type 2 diabetes mellitus
by: Olga Konstantinovna Vikulova, et al.
Published: (2010-09-01)

An experimental study of exenatide effects on renal injury in diabetic rats
by: Xiaodong Wang, et al.
Published: (2019-02-01)

Ion- and osmoregulating renal functions in patients with type 2 diabetes mellitus
by: Evgeniya Vladimirovna Balbotkina, et al.
Published: (2016-01-01)

Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice
by: Xiaoyan Bao, et al.
Published: (2020-04-01)

Construction and Evaluation of Chitosan-Based Nanoparticles for Oral Administration of Exenatide in Type 2 Diabetic Rats
by: Jian-Miao Yang, et al.
Published: (2022-05-01)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
by: Neff LM
Published: (2010-07-01)

The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study
by: Boyu Li, et al.
Published: (2020-06-01)

Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: Effect of exenatide
by: Vaghasiya Jitendra, et al.
Published: (2010-01-01)

Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus
by: Cobble Michael
Published: (2012-03-01)

Prevalence of obesity among hypertensive patients in Primary Care Clinic, Security Forces Hospital, Riyadh, Saudi Arabia 2017–2018: A prospective cross-sectional study
by: Eman A AlMarri, et al.
Published: (2020-01-01)

Kontrol altında olmayan tip 2 diyabetes mellitus hastalarında insülin tedavisinden eksenatid bazlı tedaviye geçişin etkinliği
by: Cem Onur Kıraç, et al.
Published: (2020-09-01)

Prevalence and risk factors for painful diabetic neuropathy in secondary healthcare in Qatar
by: Georgios Ponirakis, et al.
Published: (2019-11-01)

Comparison of changes in adipokine and inflammatory cytokine levels in patients with newly diagnosed type 2 diabetes treated with exenatide, insulin, or pioglitazone: A post-hoc study of the CONFIDENCE trial
by: Xubin Yang, et al.
Published: (2024-01-01)

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
by: Michael A. Nauck, et al.
Published: (2021-04-01)

SIRT1-dependent deacetylation of Txnip H3K9ac is critical for exenatide-improved diabetic kidney disease
by: Mei-jun Wang, et al.
Published: (2023-11-01)

Two-Layer Sustained-Release Microneedles Encapsulating Exenatide for Type 2 Diabetes Treatment
by: Han Liu, et al.
Published: (2022-06-01)

Exenatide for obesity in children and adolescents: Systematic review and meta-analysis
by: Bin Chen, et al.
Published: (2024-04-01)

Association between exenatide use and incidence of Alzheimer's disease
by: Bo Zhou, et al.
Published: (2021-01-01)

The first successful desensitization protocol in exenatide allergy: a case report
by: Osman Ozan Yeğit, et al.
Published: (2023-01-01)

Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats
by: Michael Klotsman, et al.
Published: (2021-05-01)

Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
by: Inaishi J, et al.
Published: (2022-02-01)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
by: Knop FK, et al.
Published: (2010-05-01)

Effects of PPARD gene variants on the therapeutic responses to exenatide in chinese patients with type 2 diabetes mellitus
by: Jinfang Song, et al.
Published: (2022-08-01)

Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus
by: Marie Pereira, et al.
Published: (2017-11-01)

Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study
by: Juyoung Shin, et al.
Published: (2012-10-01)